Technology | September 20, 2011

Boston Scientific Launches Low-Profile Coyote Peripheral Balloon Catheter


September 20, 2011 — Boston Scientific Corp. has launched its Coyote Balloon Catheter, a highly deliverable and ultra-low profile 0.014-inch balloon dilatation catheter designed to treat patients undergoing peripheral angioplasty procedures below the knee. The company has begun marketing the product in the United States, Europe and other international markets.  

Boston Scientific developed the Coyote to help physicians better treat patients with challenging obstructive lesions in the lower extremities. It features an ultra-low lesion entry profile (0.017 inch), crossing profile and a shaft optimized for high deliverability. The balloon offers rapid deflation times and is available in lengths up to 220 mm on both over-the-wire (OTW) and Monorail platforms.  

"The Coyote Balloon Catheter's low profile and ability to navigate through challenging vasculature make it ideal for treating vessels in the lower extremities," said J. A. Mustapha, M.D., director of endovascular intervention at Metro Health Hospital in Wyoming, Mich. "Its performance gives me greater confidence in being able to effectively treat patients with difficult anatomy who suffer from peripheral artery disease."

Coyote is the latest in a series of balloon catheter products introduced by Boston Scientific. In June, the company launched the Mustang PTA, a highly deliverable 0.035-inch percutaneous transluminal angioplasty (PTA) catheter designed for a wide range of peripheral angioplasty procedures.

An estimated 8 to 10 million patients in the United States alone suffer from peripheral artery disease (PAD), which is characterized by blockages in vessels of the peripheral vasculature and associated with high rates of morbidity. Balloon catheters are used in peripheral angioplasty and stenting procedures to open blocked arteries.  

For more information: www.bostonscientific.com


Related Content

News | Balloon Catheter

April 4, 2024 — The U.S. Food and Drug Administration (FDA) announced that Medos International Sàrl is recalling ...

Home April 04, 2024
Home
News | Balloon Catheter

January 18, 2024 — Summa Therapeutics, LLC announced that the first-in-man injectable angioplasty procedures for ...

Home January 18, 2024
Home
News | Balloon Catheter
Cardiovascular Systems, Inc., a medical device company developing and commercializing innovative interventional ...
Home February 25, 2022
Home
News | Balloon Catheter

February 15, 2022 – CERENOVUS, an emerging leader in neurovascular care and part of Johnson & Johnson Medical Devices ...

Home February 15, 2022
Home
News | Balloon Catheter

May 20, 2021 — Boston Scientific Corporation announced it has initiated the AGENT IDE trial for the Agent Drug-Coated ...

Home May 20, 2021
Home
Feature | Balloon Catheter | By Dave Fornell, Editor

The first devices developed for interventional cardiology were percutaneous transluminal coronary angioplasty (PTCA) ...

Home March 16, 2021
Home
Feature | Balloon Catheter

February 17, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Shockwave Medical's Intravascular ...

Home February 17, 2021
Home
News | Balloon Catheter

June 4, 2020 — Transit Scientific announced the U.S. Food and Drug Administration (FDA) cleared the XO Score ...

Home June 04, 2020
Home
News | Balloon Catheter

February 24, 2020 — Abbott has voluntarily recalled specific lots of two types of its coronary angioplasty catheters — ...

Home February 24, 2020
Home
News | Balloon Catheter

July 15, 2019 — Edwards LifeSciences is recalling the IntraClude Intra-Aortic Occlusion Device due to a risk of balloon ...

Home July 15, 2019
Home
Subscribe Now